Results 281 to 290 of about 3,116,614 (307)
Some of the next articles are maybe not open access.
Journal of Hepatology, 2015
Trabajo presentado en el 50th International Liver Congress, celebrado en Viena, Austria, del 22 al 26 de abril de ...
M. Stefanovic +7 more
openaire +1 more source
Trabajo presentado en el 50th International Liver Congress, celebrado en Viena, Austria, del 22 al 26 de abril de ...
M. Stefanovic +7 more
openaire +1 more source
Journal of Controlled Release, 2021
Hepatocellular carcinoma (HCC) is a fatal disease with limited therapeutic choices. The stroma-rich tumor microenvironment hinders the in vivo delivery of most nanomedicines. Ultra-small lipid nanoparticles (usLNPs) were designed for the selective co-delivery of the cytotoxic drug, sorafenib (SOR), and siRNA against the Midkine gene (MK-siRNA) to HCC ...
Mahmoud A, Younis +4 more
openaire +2 more sources
Hepatocellular carcinoma (HCC) is a fatal disease with limited therapeutic choices. The stroma-rich tumor microenvironment hinders the in vivo delivery of most nanomedicines. Ultra-small lipid nanoparticles (usLNPs) were designed for the selective co-delivery of the cytotoxic drug, sorafenib (SOR), and siRNA against the Midkine gene (MK-siRNA) to HCC ...
Mahmoud A, Younis +4 more
openaire +2 more sources
Clinical Genitourinary Cancer, 2014
Sorafenib promotes apoptosis through downstream pathways that can be deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy resistance in CRPC.Eligible patients were those whose disease had progressed during chemotherapy (docetaxel or mitoxantrone) or within 12 weeks of stopping either.
Andrew, Meyer +6 more
openaire +2 more sources
Sorafenib promotes apoptosis through downstream pathways that can be deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy resistance in CRPC.Eligible patients were those whose disease had progressed during chemotherapy (docetaxel or mitoxantrone) or within 12 weeks of stopping either.
Andrew, Meyer +6 more
openaire +2 more sources
World Journal of Gastroenterology
BACKGROUND Hepatocellular carcinoma (HCC) is a prevalent and aggressive tumor. Sorafenib is the first-line treatment for patients with advanced HCC, but resistance to sorafenib has become a significant challenge in this therapy.
Yong Yu +7 more
semanticscholar +1 more source
BACKGROUND Hepatocellular carcinoma (HCC) is a prevalent and aggressive tumor. Sorafenib is the first-line treatment for patients with advanced HCC, but resistance to sorafenib has become a significant challenge in this therapy.
Yong Yu +7 more
semanticscholar +1 more source
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma
Biochimica et Biophysica Acta (BBA) - General Subjects, 2018Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment.
Fan, Feng +18 more
openaire +2 more sources
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Gut, 2013Hepatocellular carcinoma (HCC), the most common tumour of the liver, develops in more than 80% of cases on patients with chronically damaged livers owing to excessive alcohol consumption, hepatitis B or C virus (HBV or HCV) infection or obesity.
openaire +2 more sources
Broadening horizons: the role of ferroptosis in cancer
Nature Reviews Clinical Oncology, 2021Xin Chen, Rui Kang, Guido Kroemer
exaly
Immunotherapies for hepatocellular carcinoma
Nature Reviews Clinical Oncology, 2021, Florian Castet, Mala K Maini
exaly